Observations placeholder
Krystexxa
Identifier
016798
Type of Spiritual Experience
None
Background
Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout.
In September 2010, the FDA approved pegloticase for marketing in the United States
A description of the experience
On May, 23, 2015: 147 people reported to have side effects when taking Krystexxa. Among them, 1 people (0.68%) has Death.